SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community rallies around its mission to revolutionize the cannabis market through cryptocurrency. Advocates emphasize its cultural significance and potential to flip big pharma, while drawing parallels to Bitcoin's disruptive impact. Community members are actively sharing links to the project's website and social media channels.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG, the memecoin on Bitcoin, is trending as community members highlight its strong fundamentals, fair launch, and growing ecosystem. Discussions revolve around upcoming exchange listings and its potential to outperform other memecoins. The community, known as the 'DOG Army,' emphasizes its organic growth and alignment with Bitcoin's ethos, further fueling interest.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as investors weigh its potential as a safe haven asset amid dollar concerns, with the community debating bullish and bearish scenarios around key price levels. Discussions include potential market manipulation, upcoming halving events, and the influence of macro factors like interest rates and geopolitical uncertainty. Bullish sentiment highlights strong trends and possible incoming surges to new levels, while bearish views point to potential retracements and market corrections.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd.

SUGP is trending due to community discussion around its low float, regained NASDAQ compliance, and a recently announced contract, drawing comparisons to other Hong Kong-based stocks that have experienced significant gains. Traders are also noting the high cost to borrow, speculating about a potential short squeeze. The company's expansion into EV infrastructure and AI-powered solutions is adding to the positive sentiment.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as traders discuss potential U.S.-China trade deal impacts and the strength of big tech companies like Apple, with community members weighing in on bullish and bearish signals. Debate centers around whether recent market behavior is indicative of a healthy consolidation or a looming correction, with some expressing concerns about potential risks in AI and regional banks. News of potential interest rate cuts, rising treasury yields, and key economic data releases are adding to the conversation.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

Root Inc. is garnering attention as community members discuss its potential, partnerships, and valuation relative to competitors like Progressive. Conversations revolve around whether the company can translate partnerships into substantial growth and if upcoming earnings will reflect this. Despite recent price declines, some investors remain optimistic, viewing it as an undervalued opportunity with long-term potential akin to early-stage Tesla or Hood.

Fuzzybear ($FUZZY) is a memecoin on the XRP Ledger (XRPL), created to honor the legacy of the well-known XRPL address ‘Fuzzybear,’ which famously placed a DEX order in 2014: 1 XRP for 1 BTC. The token embodies the spirit of decentralization and community-driven growth, focusing on fun, engagement, and organic expansion. With its unique narrative and strong community, Fuzzybear grows naturally as more supporters join the movement.

Fuzzybear

Fuzzybear ($FUZZY) is trending as community members highlight its connection to XRP and potential role within the XRP Ledger ecosystem, with some suggesting it could be the next big memecoin. Discussions also mention an upcoming event and the potential for exchange listings, fueling speculation and interest. Community members also note that David Schwartz, Ripple's CTO, recently joined a discussion about Fuzzybear on X.

SSgA Active Trust - Technology Select Sector SPDR ETF

Technology Select Sector SPDR Fund

The technology sector, represented by XLK, is seeing mixed signals with potential tariff implications and leadership shifts impacting market sentiment. Community discussions revolve around whether current levels can be sustained, and if a broader market pullback is on the horizon, especially given earnings results from major tech companies and conflicting reports regarding trade policies. Despite some analysts remaining bullish, concerns about the sector's future performance are being actively discussed.

CTX is a governance token that powers and secures the Cryptex protocol. Holders of CTX can vote on protocol upgrades for TCAP as well as all future products within the Cryptex ecosystem.

Cryptex Finance

Cryptex Finance ($CTX) is trending as traders discuss its potential for a significant price surge due to its low market cap and circulating supply, with some anticipating a run to higher price levels. Community members are closely watching volume and key resistance levels, drawing comparisons to similar low-float coins. The upcoming launch of TCAP is also generating excitement and speculation about its impact on CTX's price.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics ($CORT) is trending due to positive Phase 3 ROSELLA trial results showing improved progression-free survival for patients with platinum-resistant ovarian cancer, sparking investor optimism. The community is discussing the potential for relacorilant to become a new standard of care and its impact on the company's growth. Broader interest may also stem from Corcept's pipeline and focus on endocrinologic, oncologic, metabolic and neurologic disorders.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Markets Rebound Nicely Ahead of Q3 Earnings Season 

Even though we've seen more than a dozen companies already officially report Q3 earnings results this period, Q3 earnings season really kicks off with the release of earnings from some of the biggest banks on Wall Street.

United States Antimony Corp. (UAMY) on Friday announced that it has secured $25 million in capital through a securities purchase agreement with a prominent long-only mutual fund.&nbsp;The agreement covers the sale of about two million common shares, with the transaction expected to finalize around October 14, pending standard closing conditions.The deal is set to support the company’s ambitions across mineral development and infrastructure upgrades. Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/UAMY">United States Antimony stock</a> traded over 10% higher in Friday’s premarket. On Stocktwits, retail sentiment around the stock improved to ‘extremely bullish’ from ‘bullish’ territory the previous day amid ‘high’ message volume levels.&nbsp;US Antimony plans to allocate the funds across several strategic initiatives. Among them are plans to boost its inventory of antimony and other critical minerals, expand mineral leaseholds in Alaska and Montana, and explore the possibility of capacity increase at its Madero Smelter in Mexico.Additionally, the company is eyeing potential acquisitions in the critical minerals sector while also setting aside capital for general operational needs."We have now raised a total of $69.25 million in three separate tranches with two large institutions over the last 45 days at increasingly higher share price,” said Chairman and Chief Executive Officer of United States Antimony, Gary C. Evans.The company sells antimony, zeolite, and precious metals primarily in the U.S. and Canada.&nbsp;Last month, the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-antimony-secures-245-m-defense-contract-over-five-years-report/chDhH2ZR35a">secured&nbsp;</a>a five-year contract worth up to $245 million from the U.S. Defense Logistics Agency to contribute to the antimony stockpile.United States Antimony stock has gained over 513% in 2025 and over 1,476% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bristol-myers-squibb-to-acquire-orbital-therapeutics-in-1point5-billion-deal/ch6aDhLR3Sj">Bristol Myers Squibb To Acquire Orbital Therapeutics In $1.5B Deal</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

United States Antimony Stock Surges 10% After Company Secures $25M Capital To Expand Mineral Operations

The securities purchase agreement covers the sale of about two million common shares, with the transaction expected to finalize around October 14.

Equity

The securities purchase agreement covers the sale of about two million common shares, with the transaction expected to finalize around October 14.


United States Antimony (UAMY) stock has notched five consecutive sessions of gains amid growing investor optimism around critical mineral firms.Shares of the firm, which operates the only antimony smelters in North America, closed at an all-time high on Thursday after rising over 14% in the regular trading session, following China's imposition of export restrictions on rare earths. While antimony is not part of the rare earth group, it benefited from the positive sentiment.Retail sentiment on Stocktwits about <a href="https://stocktwits.com/symbol/UAMY">United States Antimony</a> was in the ‘bullish’ territory at the time of writing, compared with ‘neutral’ a month ago. The stock has seen a 17% uptick in follower count on the social media platform over the past month.<figure class="image"><img style="aspect-ratio:799/82;" src="https://news.stocktwits-cdn.com/UAMY_Oct_10_JPG_204471c1a4.webp" alt="UAMY’s Sentiment Meter and Message Volume as of 12:57 a.m. ET on Oct. 10, 2025 | Source: Stocktwits" width="799" height="82"><figcaption>UAMY’s Sentiment Meter and Message Volume as of 12:57 a.m. ET on Oct. 10, 2025 | Source: Stocktwits</figcaption></figure>Antimony is used in munitions, batteries, military-grade compounds, and the semiconductor industry. However, China controls 65% of global antimony and restricted exports of the critical mineral last year amid its tussle with Washington, D.C. The restrictions have brought United States Antimony into the spotlight as the sole refiner of the metalloid, whose prices have skyrocketed to over $20 per pound from $5 per pound following Beijing’s export ban.CEO Gary Evans said in a Fox Business interview earlier this week that the company could meet the growing U.S. demand within a year or two by ramping up output. Last month, the company secured a five-year contract worth up to $245 million from the U.S. Defense Logistics Agency to contribute to the antimony stockpile.Last week, President Donald Trump signed an executive order to build a key road in Alaska to connect minerals-rich, isolated parts of the state to a highway. The infrastructural development will likely help the firm to ramp up production, as it has already secured claims of over 35,000 acres in Alaska for mining to supply to its smelter in Montana.One user described the stock as undervalued and the critical minerals sector as “red-hot.”<stembedurl>https://stocktwits.com/Painman/message/631744146</stembedurl>“Get in or buy higher tomorrow,” another user said.<stembedurl>https://stocktwits.com/Knowledgeworthmore/message/631755386</stembedurl>The stock has risen over fivefold this year. Investors are now keenly waiting for the start of its Alaska operations following the acquisition of the necessary permits.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-venture-global-stock-plunge-after-hours/ch6alXaR31S">Why Did Venture Global Stock Plunge After-Hours?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

US Antimony Stock On 5-Day Winning Streak — What's Making Investors Bullish?

Shares of the firm, which operates the only antimony smelter in North America, closed at an all-time high on Thursday.

United States Antimony Corp. (UAMY) reportedly said on Tuesday it has secured a five-year contract worth up to $245 million from the U.S. Defense Logistics Agency.According to a Reuters report, the company secured a sole-source contract to supply antimony metal ingots for the defense stockpile.Retail sentiment on the <a href="https://stocktwits.com/symbol/UAMY">stock</a> remained unchanged in the ‘extremely bullish’ territory, with message volumes at ‘high’ levels, according to data from Stocktwits. Shares of the company jumped over 21% in early trading on Tuesday.Since taking office, U.S. President Donald Trump has implemented multiple executive and policy measures to strengthen U.S. access to critical minerals as part of the country’s efforts to maintain national security and economic self-reliance. Reuters noted that Antimony, which is used in munitions, batteries, and military-grade compounds, was flagged as a vulnerability in the U.S. industrial base by defense officials.“It’s incredibly meaningful for all our employees to play such a strategic role in strengthening our nation's defense readiness," USAC CEO Gary C. Evans said, according to Reuters.The report noted that U.S. Antimony Corp operates North America’s only two antimony smelters and is positioned to begin immediate fulfillment from its domestic facilities. Reuters, citing the company, said that the first delivery order is expected this week.Shares of the company have jumped 322% this year and gained nearly 860% in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/amazon-faces-ftc-in-trial-over-alleged-prime-enrollment/chDhMWHR357">Amazon Faces FTC In Trial Over Alleged Prime Enrollment Strategy: Report</a>

US Antimony Secures $245M Defense Contract Over Five Years: Report

According to a Reuters report, the company secured a sole-source contract to supply antimony metal ingots for the defense stockpile.

Strength Seen in Centrus Energy (LEU): Can Its 12.1% Jump Turn into More Strength?

Centrus Energy (LEU) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in Coeur Mining (CDE): Can Its 7.0% Jump Turn into More Strength?

Coeur Mining (CDE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

The broader market experienced mixed performance on Monday, with major indices showing volatility but ultimately closing higher. The Dow Jones Industrial Average gained 0.78%. The S&amp;P 500 rose 0.79%, and the Nasdaq Composite climbed 0.64%. However, all three major averages were in the red at one point during the trading session. Despite this, the stocks making moves on market news continued to captivate investors with their dynamic performances and strategic advancements. In this article, we will take a look at the 6 best stocks that were making moves on market news with their groundbreaking innovations and strategic advancements.Also Read: <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/stocks/biotech/quantum-biopharma-expands-reach-with-new-unbuzzd-launch-and-cutting-edge-ms-clinical-study/">This Low-Float Biotech Stock is making waves with an advanced MS diagnostic tool</a><a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/newsletter-sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like AST SpaceMobile (NASDAQ: ASTS), which shot up +533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a><h3>1. Recursion Pharmaceuticals (RXRX)&nbsp;&nbsp;</h3>Market Cap as of April 15: $2.34 Billion&nbsp;&nbsp;Recursion Pharmaceuticals (NASDAQ: RXRX) is a clinical-stage biotechnology company that leverages artificial intelligence and automation to discover and develop novel therapeutics across a wide range of diseases.First Patient Dosed: Recursion Pharmaceuticals has recently announced the dosing of the first patient in its early-stage study of REC-3565 for treating relapsed or refractory B-cell lymphomas, which marks a significant clinical milestone.Unique Mechanism: REC-3565 has a unique mechanism of action that reduces the risk of drug-drug interactions and hyperbilirubinemia, making it potentially safer and more effective.Preclinical Success: Preclinical studies showed durable tumor regressions with REC-3565, both as monotherapy and in combination with a BTK inhibitor, which indicates strong clinical efficacy.Industry Collaborations: The company has partnerships with major pharmaceutical companies such as Roche, Bayer, Merck, and Sanofi, which provides it with additional resources and market access.FDA Policy Shift: The FDA has also announced to phase out some animal testing requirements for monoclonal antibodies, which benefits RXRX’s AI-driven platform.Stock Performance:Recursion Pharmaceuticals has shown strong weekly performance with a 45.26% gain. However, it has underperformed in the month and year, with declines of 15.69% and 31.43%, respectively.<h3>2. Certara (CERT)&nbsp;&nbsp;</h3>Market Cap as of April 15: $2.29 Billion&nbsp;&nbsp;Certara (NASDAQ: CERT) provides biosimulation software and technology-driven solutions to improve the drug development process, helping biopharma companies optimize clinical outcomes.Strong First Quarter Financial Results: On April 14, Certara reported preliminary first-quarter 2025 financial results.&nbsp; The company reported a 10% revenue growth to $106.0 million compared to the first quarter of 2024, with software revenue growing by 18% to $46.4 million.Bookings Growth: The company’s bookings increased by 12% to $118 million, with software bookings growing by 22% to 40.6 million.Adjusted EBITDA Growth: Adjusted EBITDA is expected to be in the range of $33 million to $35 million, representing a 13-20% growth compared to the first quarter of 2024.Reiteration of Full-Year Guidance: Certara reiterated its full-year 2025 guidance, projecting revenue in the range of $415 million to 425 million, an adjusted EBITDA margin of 30-32%, and adjusted diluted earnings per share of 42 to 46 cents.Stock Repurchase Authorization: The Board of Directors authorized a stock repurchase program of up to $100 million, reflecting confidence in the company’s strategy and financial performance.Non-Animal Navigator Launch: Certara launched its Non-Animal Navigator solution to help biopharmaceutical companies reduce reliance on animal testing by offering strategic regulatory advice, integrated preclinical development plans, and optimized AI-enabled modeling tools.Industry Adoption: The growing industry adoption of new approach methodologies (NAMs) like AI-enabled biosimulation supports Certara’s strategic focus and enhances its competitive position.Stock Performance:Certara has had a robust week with a 57.18% increase. However, it has faced losses over longer periods, including a 19.50% decline in performance year-to-date.<h3>3. United States Antimony (UAMY)&nbsp;&nbsp;</h3>Market Cap as of April 15: $377.72 Million&nbsp;&nbsp;United States Antimony (NYSEAMERICAN: UAMY) is involved in the mining, production, and sale of antimony and zeolite products, which are used in flame retardants, batteries, and chemical applications.Lease/Option Purchase Agreement: United States Antimony has executed a new lease/option purchase agreement with an experienced prospector in Wasilla, Alaska, for lands adjacent to existing leased and staked claims, with new claims and leases totaling 17,900 acres in the Fairbanks area and 3,840 acres near Stibnite Creek.Exploration Focus: Plans to begin high-grade stibnite exploration and mining operations in early May in the Fairbanks area. Management aims to extract antimony ore from its own mining claims in Alaska to Montana by Q3 2025.Antimony Production and Global Supply: China is the world’s top producer of antimony, but its output has been declining over the past decade, making it difficult to meet global needs without new sources. Furthermore, Antimony prices have surged due to China’s export ban, which began in December 2024.Montana Smelters: The company operates two smelters in Montana with capacities of 3,840tpa and 2,400tpa for antimony processing.Stock Performance:United States Antimony has demonstrated exceptional growth across various periods, including a strong weekly gain of 66.92%. It has also seen a remarkable year-over-year growth of 1,239.51%.&nbsp;Read Now: <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/stocks/tech/u-power-makes-waves-at-bangkok-motor-show-with-groundbreaking-battery-swap-demo/">Electric Vehicle Player Is Making Waves With Groundbreaking Battery Swapping Technology</a><a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/newsletter-sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like AST SpaceMobile (NASDAQ: ASTS), which shot up +533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a><h3>4. Janover (JNVR)&nbsp;&nbsp;</h3>Market Cap as of April 15: $106.54 Million&nbsp;&nbsp;Janover (NASDAQ: JNVR) provides online platforms for commercial real estate and small business loans, connecting borrowers with lenders using data-driven digital solutions.New Treasury Strategy: Janover announced a new treasury policy on April 4, 2025, to accumulate crypto assets, starting with Solana (SOL). This strategy aligns with the company’s goal of providing investors economic exposure to SOL.Significant SOL Purchases: Janover made substantial purchases of Solana (SOL) tokens, totaling $21.2 million across three transactions. These purchases have brought the company’s total SOL holdings to 163,651.7.Staking and Revenue Generation: The company will begin staking its SOL position immediately, generating revenue while supporting the Solana network. Staking rewards are also planned to be reinvested, which will further enhance cryptoasset holdings.Recent Financing Round: Janover has also raised $42 million in a financing round from investors including Pantera Capital and Kraken. These funds are specifically allocated for acquiring digital assets.Stock Performance:Janover has seen explosive growth, with a week-over-week performance of 130.20% and a remarkable 1707.42% increase in the month.<h3>5. Skye Bioscience (SKYE)</h3>Market Cap as of April 15: $82.40 MillionSkye Bioscience (NASDAQ: SKYE) is a pharmaceutical company focused on developing cannabinoid-derived molecules to treat glaucoma and other diseases with unmet medical needs.Significant Weight Loss in Preclinical Study: On April 15, Skye Bioscience announced over 30% weight loss in a diet-induced obesity model when nimacimab was combined with tirzepatide, which showcases its strong efficacy and potential as a combination therapy.Comparable Efficacy to Monlunabant and Tirzepatide: Nimacimab alone achieved 23.5% weight loss, comparable to other leading obesity drugs like tirzepatide and monlunabant, which indicates robust monotherapy potential.Differentiated Mechanism: Nimacimab’s non-competitive allosteric binding to the CB1 receptor provides a differentiated mechanism compared to monlunabant and has potentially fewer neuropsychiatric side effects.Superior Potency in High Agonist Conditions: In vitro data showed nimacimab’s potency remained stable under high agonist conditions, while monlunabant’s effectiveness was significantly impacted, which indicates superior performance in disease states like obesity.Phase 2a Data: Top-line data from the Phase 2a CBeyond study is expected in late Q3/early Q4 2025, which will provide investors with near-term clinical validation of nimacimab’s efficacy.Focus on Metabolic Health: Skye’s focus on developing next-generation molecules for metabolic health disorders aligns with the growing demand for effective obesity treatments in the market.First-In-Class Therapeutic Potential: Nimacimab’s mechanism of action as a negative allosteric modulating antibody for CB1 inhibition positions it as a first-in-class therapeutic with clinical and commercial differentiation.Stock Performance:Skye Bioscience has had a mixed performance, with a significant weekly gain of 143.32% but a modest monthly gain of only 15.41%.<h3>6. Aerovate Therapeutics (AVTE)</h3>Market Cap as of April 15: $79.12 MillionAerovate Therapeutics (NASDAQ: AVTE) is a biotechnology company developing inhaled therapies for rare cardiopulmonary diseases, with a lead candidate targeting pulmonary arterial hypertension.Expected Cash Dividend: Aerovate Therapeutics expects to declare a cash dividend in the range of $67.6 million to $69.6 million in the aggregate, based on its estimated net cash immediately prior to the closing of its merger with Jade Biosciences, which was announced on October 30, 2024.Merger Status: The Merger remains subject to approval by Aerovate’s stockholders and other closing conditions. The special meeting for stockholder approval is scheduled for April 16, 2025, with the Closing expected on or about April 28, 2025.Dividend Declaration: The official declaration of the Cash Dividend is subject to approval by the Aerovate board of directors and is expected to be announced later this month.Payment Details: The dividend will be paid with an estimated $2.40 per share based on 28,985,019 shares outstanding as of April 9, 2025. The payment date is scheduled for April 29, 2025.Purpose of Merger: The merger will combine Aerovate’s expertise in rare cardiopulmonary diseases with Jade’s focus on developing best-in-class therapies for autoimmune diseases. This combination is expected to create a robust pipeline and enhanced capabilities to address critical unmet medical needs.Stock Performance:Aerovate Therapeutics has exhibited extraordinary performance, with a week-over-week gain of 2914.67% and a month-over-month gain of 2975.95%, making it a standout performer among the stocks listed.<h3>Conclusion</h3>As we conclude our review of these promising companies, it’s clear that these stocks making moves on market news are not just fleeting trends but represent substantial investment opportunities. Each company discussed here is leveraging cutting-edge technology, strategic partnerships, and market shifts to propel their businesses forward, making them standout choices for discerning investors.&nbsp; &nbsp;Read Next: <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/featured/top-4-stocks-poised-for-big-gains/">4 Stocks Poised for Big Gains Amid Major Transformations</a> &nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/newsletter-sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like AST SpaceMobile (NASDAQ: ASTS), which shot up +533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Do you have a stock tip or news story suggestion? Please email us at&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="mailto:Invest@WealthyVC.com">Invest@WealthyVC.com</a>.Disclaimer: Wealthy VC does not hold a position in any of the stocks, ETFs or cryptocurrencies mentioned in this article.

Small Cap News Movers: Your Daily Digest of Stocks Making Moves on Market News

Others

Perpetua Resources Announces Continued Cooperation with U.S. Antimony

Perpetua Resources Announces Continued Cooperation with U.S. Antimony Perpetua Resources Announces Continued Cooperation with U.S. Antimony PR Newswire BOISE, Idaho, Dec. 9, 2024 U.S. Antimony...

Shares of United States Antimony Corp (UAMY) have rallied over the past week in the wake of escalating US-China trade tensions, reaching a 52-week high on Friday, heating up retail chatter. Earlier this week, China banned the exports of rare minerals, including antimony, gallium, and germanium, to the US, a move that could potentially mean an opportunity for companies like United States Antimony. &nbsp; Antimony is a scarce commodity, and United States Antimony sees ongoing supply issues and trade restrictions and resulting worldwide antimony metal prices as an opportunity for the company. It said in a recent release that market prices of the precious metal increased from $5.31 per pound on December 31, 2023 to about $17 per pound as of November 8. Rare minerals are also widely used in the industrial sector United States Antimony recently reported its third-quarter results, which saw its revenues rise 17% to $2.421 million and its gross profit increase 65% to $426,000.&nbsp; Loss from continuing operations was $683,000 for the quarter, up from $185,000 in the same period last year. The rise was “directly related” to the company's expanded scope of operations. Retail sentiment around the stock has turned bullish. Many Stocktwits users were optimistic about the company's prospects, given the application of the rare minerals. <stembedurl>https://stocktwits.com/theleftnutt/message/595451429</stembedurl><stembedurl>https://stocktwits.com/algo888/message/595444278</stembedurl> China’s decision to ban exports appeared to be in reaction to the U.S. curbing exports to 140 companies earlier this week. United States Antimony is up 602% year-to-date. &nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail sentiment around the stock has turned bullish| Image source: WIkimedia Commons

United States Antimony Stock Rallies On Potential Opportunity From China Precious Metals Ban: Retail Bullish

Retail sentiment on the stock has turned bullish. 

U.S. Antimony (UAMY) Announces Plan to Discontinue Latin America Operational Activities

THOMPSON FALLS, MT / ACCESSWIRE / March 11, 2024 / United States Antimony Corporation ('USAC' or 'U.S. Antimony' or the 'Company'), (NYSE:UAMY) announces plan to discontinue all Latin America...

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$11.39
Prev Close	$12.56
Open	$11.01
Dividend Yield	0.00%
50-Day Moving Average	$6.57
Beta	1.20
Avg. Volume	8.14M
PE Ratio	-1,243.33

52-Week High	$19.71
52-Week Low	$0.4901
Market Capitalization	$1.55B
EPS (Annual)	-$0.016
Price to Book	35.57
Revenue Per Employee	$240,934.87
Enterprise Value/EBITDA	N/A

UAMY
United States Antimony Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest UAMY News

UAMYUnited States Antimony Corp